May 24, 2017 13:11 pm UTC| Business
OXNARD, Calif., May 24, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that it has received...
May 24, 2017 13:11 pm UTC| Business
OXNARD, Calif., May 24, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that it has received...
May 24, 2017 13:11 pm UTC| Business
OXNARD, Calif., May 24, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that it has received...
May 24, 2017 13:11 pm UTC| Business
OXNARD, Calif., May 24, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that it has received...
May 24, 2017 13:11 pm UTC| Business
OXNARD, Calif., May 24, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that it has received...
May 24, 2017 13:11 pm UTC| Business
OXNARD, Calif., May 24, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that it has received...
May 24, 2017 13:11 pm UTC| Business
OXNARD, Calif., May 24, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that it has received...